Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 20, 2015Diabetes Care

Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

RHRobert R. HenryPennington Biomedical Research CenterPTPayal ThakkarJohnson & Johnson (United States)CTCindy S.W. TongJohnson & Johnson (United States)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Henry et al. (2015) studied this question.

synapsesocial.com/papers/69d76887447a5ff6a2b8a70chttps://doi.org/10.2337/dc15-1730
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events2015 · 97 citations
  2. 2Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients2014 · 1,145 citations
  3. 3Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition2015 · 849 citations
  4. 4Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial2014 · 232 citations
  5. 5Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study2014 · 238 citations